List of Bioinformatics Companies with Phase 1 Active Clinical Trial - 59

A2A Pharmaceuticals designs computationally optimized small molecule therapeutics for the treatment of cancer and antibiotic resistant bacterial infections. Our two oncology programs are focused on inhibiting essential protein-protein interactions in leukemia and in diverse solid tumors. These interactions are critical for cancer progression, but non-essential in normal cells. The antibiotic programs target biosynthetic enzymes in gram-negative bacteria, in pathways not found in humans. The targets selected have no clinically used therapeutics, minimizing susceptibility to resistance; and unlike the numerous follow-on antibiotics currently in development. Our approach integrates interdisciplinary ingenuity with computational tools to design new drug candidates using our proprietary SCULPT platform. Experimentally determined target characteristics guide the selection and placement of fragments to recapitulate key contact points of proteins and/or ligands known to bind. Fragments are incorporated into the target-specific construction of combinatorial in silico libraries, which are designed based on synthetic feasibility. Libraries consisting of thousands to millions of small molecules are iteratively built, and computationally evaluated for potency and optimal ADMET properties. The final selection is made from dozens of iterations, totaling upwards of 100 million compounds.

Overview: AccutarBio employs artificial intelligence to revolutionize drug discovery. With capabilities in side chain flexible mode ligand docking, virtual screening, and drug ADME property prediction, Accutar’s platform beats the industry standard in computation-aided drug design. The company’s hybrid based approach, which uses computational drug design followed by wet lab validation, greatly reduces the time and cost necessary for traditional drug discovery efforts. Accutar is committed to building strong partnerships, and collaborates across academia and the pharmaceutical industry to solve interdisciplinary problems. The company was founded in 2015 and has locations in both Shanghai, China and New York, NY. Products & Services: Accutar offers two software packages: Chemi-Net and Orbital. Chemi-Net is a molecular graph convolutional network for accurate drug property prediction. It was recently shown to improve the accuracy of ADME property prediction by a large margin in comparison to the widely-used methods https://arxiv.org/abs/1803.06236. Orbital is a deep neural network based docking platform. The prediction accuracy of protein-ligand complex (holo) from ligand free state (apo) structure is significantly higher than current standards. In addition to these tools, AccutarBio offers services in virtual screening for lead discovery; intelligent-SAR for lead optimization and drug property prediction.

Ajax Therapeutics is a biotechnology company developing precision therapies for blood cancers called hematologic malignancies. The company has a unique partnership with Schrödinger, Inc. to develop novel small molecules targeting cytokine signaling pathways for hematologic malignancies.

Alcyone Therapeutics is a biotechnology company pioneering next-generation precision gene-based therapies for complex neurological conditions. The company integrates innovation in neuroscience, precision dosing platforms, and manufacturing capabilities to deliver transformative therapies to patients. Alcyone leverages the synergy between FalconTM, the company’s proprietary intrathecal precision dosing and biodistribution platform that incorporates deep knowledge of cerebral spinal fluid (CSF) dynamics, computational modeling, and bioengineering, and four novel gene-based therapeutics platforms developed at the Abigail Wexner Research Institute at Nationwide Children’s Hospital (AWRI). This comprehensive approach allows for the optimization of central nervous system (CNS) dosing and delivery to better target the pathophysiology and anatomy specific to various neurological diseases. Alcyone’s lead programs utilize X chromosome reactivation for X-linked disorders and targets the treatment of Rett syndrome, and gene replacement for the treatment of IGHMBP2-related disorders including spinal muscular atrophy with respiratory distress type 1 (SMARD1) and Charcot Marie Tooth disease type 2S (CMT2S).

Alterome Therapeutics, Inc. is a precision oncology biotech developing alteration-specific therapeutics to address high value and validated oncogenic drivers. We are a team with expertise in multiple areas of science and operations, dedicated to co-elevating toward our vision to bring life-changing and life-saving therapies to cancer patients. We believe in our journey, in each other, and in our ability to collaboratively develop therapies that will help end cancers. Thus, we seek the best people for our company and provide the resources they need to grow, develop, and accomplish our collective goals. We are moving forward with humility & empathy, fearlessness & resilience, with a sense of inclusion & belonging, open communication and a deep trust. And…we manage to have a lot of fun along the way!

Amai develops novel proteins that answer the needs of consumers and industry. The first application is sweet protein, inspired by nature, and built with biology through a natural fermentation process. With its pro-protein platform, the company creates new breakthroughs which are set to shape the future of proteins.

Axcynsis Therapeutics is at the forefront of developing cutting-edge Antibody Drug Conjugate (ADC) therapies. Our team's profound expertise, pioneering and proprietary ADC technology platform, enduring IP and know-how, substantial market opportunities, and strategic and effective execution position us as industry leaders in innovative cancer treatment solutions. At Axcynsis, our groundbreaking Matrix Optimization Platform is the cornerstone of our research and development efforts. This cutting-edge platform empowers us to swiftly explore numerous linker and payload combinations alongside our proprietary antibodies. We further harness state-of-the-art technologies, including an exclusive payload library derived from an FDA-approved drug and site-specific conjugation methods. These innovations are strategically employed to enhance the safety and quality of our ADCs. With two potential best-in-class programs on track for clinical trials by 2025 and a third program making headway toward IND status, we are poised for significant value creation and breakthroughs in cancer therapeutics. Based in Singapore, we plan to expand our clinical development operations to the United States by 2024. Join us on our journey to transform cancer treatment and make a meaningful impact in biotechnology. Axcynsis is at the forefront of developing life-changing ADC therapies, and we invite you to be a part of our innovative and dedicated team as we pioneer the future of cancer therapeutics.

AyuVis is a start-up biopharmaceutical company focusing on developing New Molecular Entities (NME) as immune modulating, anti-microbial, and anti-inflammatory drugs. Our pipeline of drug candidates is based on a new platform technology that modulates macrophages in the innate immune system to restore balance while fighting both infection and inflammation. Stimulating these macrophages produces a rapid therapeutic response throughout the body as we have seen in our strong preclinical data. This is unlike any existing immunotherapies today - immunotherapies which in total have annual sales of $70B. Because the antimicrobial action of our compounds is through the activation of phagocytosis, the development of multidrug resistance is not anticipated. Our goal is to save and improve lives, reduce hospital costs, & provide an effective treatment to diseases like BPD, VAP, and ARDS with no adverse side effects that are seen with the current alternatives. Our lead candidate is Orphan Drug and Rare Pediatric Disease Designated by the US FDA for the prevention of bronchopulmonary dysplasia (BPD) in at-risk preterm infants. BPD is a rare pediatric lung disease in preterm babies caused by inflammation from supplemental oxygen required for survival in the NICU and is the second leading cause of death in preterm babies. An average of 112 preterm babies die per month in the US due to the lack of an effective therapy and survivors require ongoing care. AyuVis has 2 patents approved by the USPTO and more countries which include composition of matter of our compounds, methods of use, formulations, and more.

BGI was founded in 1999 as a research organization to support the Human Genome Project. Over the years, BGI’s in-house research has contributed to the development of the field of Genomics in significant ways, as evidenced by a wealth of peer-reviewed publications in prestigious scientific journals. Today, BGI is actively participating in the fields of Cancer Research, Bio-sustainability and Personalized Medicine through a global network of collaborators. BGI Genomics is the world’s leading provider of genomic and proteomic services, now serving customers in more than 66 countries. We provide academic institutions, pharmaceutical companies, health care providers and other organizations with integrated genomic and proteomic services and solutions across a broad range of applications spanning basic and translational research, drug discovery, agriculture and health care. To provide these services, we operate a large network of service Laboratories in China, Hong Kong, the US and Europe. Our customers benefit from the highest level of sequencing experience in the world to support their research and drug discovery projects. Our service laboratories operate under strict internationally recognized quality systems, such as those from CAP and ISO. More recently, BGI developed and launched its own DNBseq™ sequencing technology, based on DNA Nanoball sequencing technology that was invented in our Complete Genomics research facility in Silicon Valley, California. Scientists around the world now rely on DNBseq NGS services for the highest quality data at the lowest cost.

BostonGene is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer.

At CAMP4 Therapeutics, we are pioneering a novel approach to programmable therapeutics. We combine a deep understanding of regulatory RNA and gene expression with a complementary and customizable oligonucleotide modality. Our platform’s proprietary insights enable us to harness the power of RNA to upregulate the expression of genes and unlock the potential to create treatments for hundreds of diseases affecting millions of patients. Join us at the forefront.

CENTOGENE’s mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases. We integrate multiomic technologies with the CENTOGENE Biodatabank – providing dimensional analysis to guide the next generation of precision medicine. Our unique approach enables rapid and reliable diagnosis for patients, supports a more precise physician understanding of disease states, and accelerates and de-risks targeted pharma drug discovery, development, and commercialization.

Circle Pharma initiated operations in June 2014 with seed funding from Pfizer, Inc. and Mission Bay Capital, LLP; we received additional seed funding from ShangPharma Investment Group Limited in November 2015. They recently raised Series B and Series C financing from The Column Group and NextTech Invest. Circle Pharma design and develop bioavailable macrocyclic peptide therapeutics against important clinical targets. They do this by applying a computational structure-based design approach that combines physics (conformational modeling), chemistry (innovative molecular components) and biology (protein target structure and function). They have selected intracellular protein-protein interactions that play key roles in cancer as the initial target group for our internal pipeline development. Circle is taking a new approach to the development of macrocylic peptide therapeutics that is based on the pioneering work of its founders to understand and computationally predict drug-like properties of macrocycles. Circle is advancing this understanding to design novel, inherently permeable macrocyclic peptide drug candidates against Circle’s internal targets and those of our collaboration partners. Circle Pharma workflow includes the use of proprietary algorithms to design large, conformationally diverse, virtual libraries of cell permeable macrocyclic scaffolds that incorporate natural and non-natural backbone components. They deploy these virtual scaffold libraries in subsequent design steps that include the incorporation of functional side chains selected for both target binding and maintenance of permeability. Candidate compounds are synthesized and tested for both permeability and target affinity and the results are used to inform subsequent design cycles.

Genetic testing, direct to consumerCOVID-19: EUA (05/2020) for their LAMP (Loop-mediated amplification) and uses three SARS-CoV-2-specific primer sets targeting the SARS-CoV-2 nucleocapsid gene (N), the envelope gene (E), and the ORF1a region.

Cyclarity Therapeutics, Inc. is pursuing a mission to treat, cure, and reverse atherosclerosis. The company aims to deliver simple and affordable therapies for cardiovascular disease and other chronic diseases of aging. Cyclarity is continuing to develop technology to treat the underlying causes of age-related diseases.

Empatica is an affective computing company, focused on human data analytics. We develop groundbreaking wearable devices with medical quality sensing. Our technology comprises a set of wristband, software running on smartphone and desktop computing, plus real time syncing with a cloud computing service.

Evidation creates new ways to measure and improve health in everyday life—making proactive, personalized, and truly human-centered healthcare possible. By connecting directly with millions of individuals, Evidation harnesses real-world data to deeply understand health experiences, rapidly and at scale. Evidation’s privacy-centric digital health measurement and engagement platform uses data science and machine learning to translate these everyday insights into high-impact health guidance, treatments, and tools. Founded in 2012, Evidation is headquartered in California with employees working around the globe.

Freenome is a private biotech company focused on developing blood tests to detect cancer early and make screening accessible for everyone.

Genetesis is a rapidly growing medical imaging company leveraging data science and biomagnetism in the fight against cardiovascular disease.

GigaGen, a subsidiary of Grifols, is advancing transformative antibody drugs for immune deficiency, infectious diseases and checkpoint resistant cancers by leveraging industry-leading, single-cell technologies. GigaGen’s novel technology platforms uniquely capture and recreate complete immune repertoires as functional antibody libraries. This approach has enabled the creation of first-in-class recombinant polyclonal antibody therapies for the treatment of infectious diseases. GigaGen’s lead oncology asset, GIGA-564, is an anti-CTLA-4 monoclonal antibody that has demonstrated improved anti-tumor efficacy in vivo through a unique mechanism of action. GigaGen is leveraging its proprietary technology platforms for the continued discovery of novel recombinant polyclonal drugs and monoclonal antibodies to treat life-threatening diseases.

Meet your business challenges head on with cloud computing services from Google, including data management, hybrid & multi-cloud, and AI & ML.

At Harbinger Health, our mission is to change the cancer paradigm by taking a proactive approach to cancer detection and prevention. We envision a future where cancer is no longer a life-altering event, but a routine health problem that can be addressed with early intervention. To achieve this, we have developed proprietary solutions for cancer pre-emption, starting with blood-based tests that can detect cancer before it even becomes visible. By identifying biological programs that are the root cause of cancer, we can enable early-stage and pre-disease identification, leading to truly personalized and effective cancer care for everyone. With Harbinger Health leading the way, we believe that a cancer-free future is not only possible but within reach, for everyone.

Helicore Biopharma, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics to address obesity and related metabolic conditions. The company is advancing a portfolio of next-generation treatments with a novel approach to glucose-dependent insulinotropic peptide (GIP) antagonism. Helicore's proprietary platform leverages monoclonal antibodies that bind circulating GIP ligand, designed to improve the efficacy, dosing, and tolerability of anti-obesity therapies. Helicore is rapidly advancing a differentiated portfolio that may deliver superior treatment outcomes through enhanced efficacy, tolerability and convenient dosing regimens. Following the close of a $65M Series A financing in January 2024, Helicore is well-positioned to drive progress in this critical area of unmet need. For more information, visit www.helicore.com.

By taking a simple blood test from the mother-to-be, we can read the fetal DNA! No more risky, complicated and late invasive tests like amniocentesis - we are revolutionizing the way prenatal testing is done.

At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina's innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.

Innovac Therapeutics is a biotechnology company dedicated to developing innovative vaccines for patients with unmet medical needs, using our proprietary RNA technology.

Inocras is a company for whole genome sequencing, providing a comprehensive view of a patient's entire genetic profile through WGS analysis and interpretation. Focusing on cancer and rare diseases, we aspire to fundamentally change how the world treats genetically driven diseases with an unsurpassed WGS databank and an integrated platform for generating, collecting, and analyzing genomic data.

IntegraGen is an OncoDNA group company specializing in the genomics of cancer and rare genetic diseases. Backed by highly competent and qualified teams, IntegraGen is a leading player in DNA sequencing services and genomic data interpretation software. The company runs one of the largest NGS labs in France and operates for research institutes of excellence. As part of OncoDNA group, IntegraGen leverages the power of next generation sequencing with the mission of delivering the promise of precision medicine to patients. IntegraGen has about 50 employees and generated €9 million of revenue in 2020. Based in France, IntegraGen is also present in the United States and is part of the OncoDNA group which works with an international network of 35 distributors. The Group also provides biomarker testing and clinical interpretation tools to guide treatment and monitoring of late stage solid tumors and accelerate the development of new cancer drugs. IntegraGen is listed on Euronext Growth in Paris (ISIN: FR0010908723 - Mnemo: ALINT - Eligible PEA-PME).

Invivoscribe® is a global leader dedicated to Improving Lives with Precision Diagnostics®, advancing the quality of healthcare by providing innovative products and clinical services for oncology. Our Streamlined CDx® (companion diagnostic) model accelerates the development of novel therapeutics, enabling personalized approaches to patient care. With products manufactured in our state-of-the-art cGMP facility, we provide a comprehensive range of platform agnostic assays, reagents, controls and software for clonal gene rearrangements, translocations, gene mutation testing, and measurable residual disease (MRD). Invivoscribe’s products consistently surpass industry and regulatory standards and play a crucial role in identifying, stratifying and monitoring hematologic cancers, enabling scientific advancements and empowering clinicians to make informed treatment decisions. Our subsidiary, the Laboratory for Personalized Molecular Medicine® (LabPMM®), offers extensive clinical diagnostic and biopharma services for the detection and monitoring of myelo- and lymphoproliferative disorders. The LabPMM network performs globally standardized flow cytometry and molecular testing services for pharmaceutical and healthcare organizations, providing results that are critically important for patient care in the U.S., Europe, and Asia. Join us in our mission to revolutionize oncology diagnostics and improve patient outcomes worldwide. Visit our website to discover how Invivoscribe’s ecosystem is driving advancements in precision medicine.

Kiromic BioPharma is an allogeneic Gamma Delta T-cell therapy company featuring unique, proprietary, end-to-end bioinformatic, AI targeting, and manufacturing technologies to address solid tumors. We are a clinical-stage, fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) 2.0 target discovery engine to develop and commercialize cell therapies focusing on immuno-oncology. Kiromic is developing a multi-indication allogeneic cell therapy platform that exploits the natural potency of Gamma Delta T-cells to target solid tumors. Kiromic’s DIAMOND® AI is where data science meets target identification to dramatically compress the years and hundreds of millions of dollars required to develop a live drug. The Company maintains offices in Houston, Texas. To learn more, visit www.kiromic.com and connect with us on Twitter and LinkedIn.

Koneksa is a leading patient-centric digital biomarker company for the pharmaceutical and biotechnology industries that develops end-to-end solutions for remotely collected clinical data. Koneksa supports agile decision-making in drug development and market strategy. By delivering integrated solutions for efficient trial designs that produce more meaningful data, Koneksa aims to revolutionize effect detection in clinical research.

Leidos is a Fortune 500® innovation company rapidly addressing the world’s most vexing challenges in national security and health. The company's global workforce of 48,000 collaborates to create smarter technology solutions for customers in heavily regulated industries. Headquartered in Reston, Virginia, Leidos reported annual revenues of approximately $15.4 billion for the fiscal year ended December 29, 2023. Leidos was cited for the meaningful work employees perform that is challenging, impactful, and aligned with our customers’ missions as reasons professionals want to work and stay at our company. Leidos has also been named to lists including Forbes’ Best Employers for Diversity, Forbes’ America’s Best Employers for Women, Military Times Best for Vets Employers, and Ethisphere Institute’s World's Most Ethical Companies®. Employees enjoy career enrichment opportunities available through mobility and development and experience rewarding relationships with supportive supervisors and talented colleagues and customers. Employees appreciate our flexible work environment, allowing for and encouraging a true work-life balance. Our professionals are also excited about our Employee Resource Groups, like the Collaborative Outreach with Remote and Embedded Employees (CORE), which strives to create an environment where every employee, regardless of location, feels fully engaged as a valued employee of Leidos. Your most important work is ahead, visit careers.leidos.com for our latest opportunities.

The first health wearable monitoring glucose non-invasively. New health insights are unlocked through real time combination of signals. Precision glucose measurements without piercing the skin. This is a world's first. Why glucose? Small irregularities in glucose metabolism compound over time. The progression from healthy to disease is often imperceptible. Awareness is a powerful tool for prevention.

Massive Bio collects and curates the latest scientific knowledge in genomics of cancer, connects with clinical information incorporate all new discoveries in treatment plans.

Microsoft is a technology company that offers a wide range of software, cloud computing services, hardware, and artificial intelligence solutions.

Mirxes is a Singapore-headquartered biotechnology company whose mission is to save lives through early, actionable, and personalized diagnoses across the care continuum. We are Asia-centered, starting with Southeast Asia, and have global ambitions. We have research, development, manufacturing, and clinical diagnostic operations in Singapore, USA, Japan, and China. We have sales and distribution networks worldwide. Our flagship product is GASTROClear, the world’s first molecular blood test for early detection of gastric cancer, able to detect around 90% of patients with Stage I and II cancers. We continue to build a comprehensive cancer portfolio with early detection tests for lung and thyroid cancer (2022), colorectal and breast cancer (2023), liver and ovarian cancer (2024). We are concurrently building a precision oncology portfolio to provide clinical insights for the complete patient journey. MiRXES was spun off from A*STAR’s Bioprocessing Technology Institute in 2014 to commercialize an industry-leading qPCR-based technology for microRNA detection. Our ID3EAL discovery tool and workflow has been adopted by top academic and industry partners globally and is backed by the world’s first industry standard for microRNA-base diagnostics. Our versatile platform technology and capabilities have broad applications in the discovery of biomarkers and diagnosis of diseases. We are starting with early cancer detection, but we will also be addressing unmet clinical needs in cardiovascular, metabolic, and infectious diseases. We responded to COVID-19 by leveraging our capabilities to mass produce and distribute over 5 million units of the Fortitude COVID-19 RT-PCR test. This made-in-Singapore diagnostic test, developed by A*STAR and Tan Tock Seng Hospital, has been deployed in 13 Singapore hospitals and clinical labs and exported to over 45 countries worldwide. Post-COVID, we will leverage this network to commercialize multi-cancer early detection tests.

NeoCura is a high-tech enterprise that relies on AI technology to create an RNA technology platform and conduct R&D of innovative drugs. The company has built multi-omics big data acquisition platforms and multiple bioomics databases. It uses AI and bioinformatics technology to conduct in-depth drug target mining and fully automated drug design for innovative RNA technology platform upgrades and drug research. It has established leading R&D centers and production centers in Beijing, Shenzhen, and Guangzhou to support pipelines development, platform upgrades, and clinical demand.

We are Nested Therapeutics, a biotech company inspired by service and driven by a desire to make a meaningful impact. We are creative innovators who challenge our own assumptions as we strive to find new, overlooked areas of opportunity to design therapeutics for a perfect fit. We embrace diverse perspectives and experiences in a space for everyone to add value and be valued in return, with the purpose of building solutions together while having fun doing it. United through our common vision for the future of precision medicine and our shared values of service, humility, impact, invention, and connection, we’re determined to dramatically expand the reach of precision medicine and make first- and best-in-class precision oncology treatments available to a larger population.

Notable is a clinical-stage platform therapeutic company developing a new class of precision medicines: predictive precision medicines. Notable aims to be the leader in predictive precision medicine and revolutionize the way in which patients seek and receive treatment: patient population by patient population, and cancer by cancer. By transforming historical standards of care, Notable expects to provide dramatic impact for patients and the healthcare community. Notable's proprietary Predictive Precision Medicines Platform replicates ex vivo the clinical response of patients to cancer treatments with high fidelity, through its optimized integration of biological assay conditions, dynamic signal analysis, and AI-driven in-silico translation into predictive algorithms. Using its high-fidelity platform, Notable can identify and select clinically responsive patients prior to their treatment and fast-track clinical development in this patient population. Notable has created a targeted, triple de-risked in-licensing strategy and a fast-track clinical development approach that delivers a product's medical impact and commercial value faster, higher, and more likely than traditional drug development.

Ophiomics is a Biotech company developing new diagnostic products and services integrating bioinformatics and genomics in support of diagnostic, prognostic, pharmacogenomics and clinical follow up in liver cancer.

For 85 years, PerkinElmer has pushed the boundaries of science in our food, industrial, life science and environmental markets. In addition to innovative laboratory technologies, our OneSource services division delivers a highly trained, experienced, and collaborative team of service engineers with solutions scalable and customizable to serve laboratory needs. We’ve always pursued science with a clear purpose – to help our customers achieve theirs. Our expert team brings technology and intangibles, like creativity, empathy, diligence, and a spirit of collaboration, in equal measure, to fulfill our customers’ desire to work better, innovate better, and create better. PerkinElmer is a leading, global provider of technology and service solutions that help customers measure, quantify, detect, and report in ways that help ensure the quality, safety, and satisfaction of their products. Science with Purpose. Learn more at www.perkinelmer.com.

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves biopharmaceutical customers, universities and non-profits, diagnostics companies, and government entities. The company has partnership with Berry Genomics; Natera, Inc.; and MapKure, LLC. Personalis, Inc. was founded in 2011 and is headquartered in Menlo Park, California.

PinkDx is an early-stage company whose vision is to positively impact the health of women throughout their life journey. We focus on addressing the medical problems that women uniquely face by applying sophisticated scientific approaches to resolve them and provide answers that have an immediate, positive impact on their lives. Our first indication will focus on overcoming diagnostic challenges for women who present with general symptoms that could signal a gynecological cancer. Led by a team of diagnostics industry veterans, PinkDx is privately held, with funding from prominent biotechnology investors, including Catalio Capital Management, The Production Board, Mountain Group Partners, Byers Capital and Mayo Clinic.

Precision for Medicine is an industry-leading global clinical research services organization, purpose-built to improve the clinical research and development process for new therapeutics. Our novel approach integrates clinical operations excellence, with laboratory expertise, and advanced data sciences to inform every step. This maximizes our clients’ insight into patient biology, delivering more predictable trial outcomes and accelerating clinical development. We apply our expertise to trials at all stages—from early development through approval—with embedded experience in oncology and rare disease. With over 2000 dedicated professionals and 35 offices worldwide, we stand ready to help accelerate life-changing treatments anywhere around the globe.

ProMIS Neurosciences is focused on the treatment of Alzheimer’s disease, amyotrophic lateral sclerosis and multiple system atrophy through the discovery and development of antibodies selective for toxic misfolded proteins driving these diseases.

PulseMedica has developed a proprietary real-time 3D imaging and laser targeting system for precise retinal surgery. Our patented next generation ultrafast femtosecond laser ophthalmic treatment will enable treatment for retinal diseases such as age-related macular degeneration (AMD) and glaucoma, for which there is currently no cure. PulseMedica is a company based out of Edmonton, AB, Canada.

QIAGEN is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of December 31 2021 QIAGEN employed more than 6,000 people in over 35 locations worldwide. Further information can be found at www.qiagen.com.

We are an end-to-end biotech developing transformational medicines, with technology at our core. Our ambition is to understand human biology in an unprecedented way; discovering therapies that will treat some of life's most devastating diseases. We leverage single-cell and multi-omics measurements directly from patient tissue, functional assays and machine learning to drive disease understanding — from cause to cure. Medicines born from high-resolution biology, machine learning and clinical insights. Our Lab-in-the-Loop seamlessly integrates single-cell analysis, genomics and machine learning. We have developed powerful technologies which we apply to select druggable targets and develop transformational medicines.

Remix launched in 2020 with a vision to transform patient's lives through modulation of RNA processing. Our breakthrough science provides a path to identify small molecules that impact the expression of disease driving mRNAs and proteins. We take on the challenge of addressing drug targets in diseases of high unmet medical need to bring new therapeutic options to patients. Remix has a commitment to demonstrate the highest levels of scientific integrity with urgency because those patients are counting on us to deliver. With an in-house technology platform built from scratch, we have rapidly generated multiple drug discovery programs that are advancing towards the clinic.

Sana is a digital heath company driven by 25 years of research into relief for symptoms of chronic pain and insomnia. Sana is developing the first non-invasive, comfortable bio-therapeutic device capable of inducing a deep restorative state of relaxation to alleviate pain and tension. The device provides relief in just 10 minutes through the use of audio-visual neuromodulation, and is currently undergoing FDA certification and clinical trials.

Schrödinger, Inc. provides computational platform to accelerate drug discovery and materials design for biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. The company operates through two segments, Software and Drug Discovery. Its segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment develops a pipeline of preclinical and clinical drug discovery programs through its computational platform in collaboration with pharmaceutical companies. Schrödinger, Inc. has strategic collaborations with Twist Bioscience Corporation; Thermo Fisher Scientific to extend the use of cryo-EM in connection within silico compound screening to accelerate drug discovery; and Bristol Myers Squibb Company to discover, develop, and commercialize therapeutics in multiple disease areas. The company was founded in 1990 and is based in New York.

Scipher Medicine is building the future of patient treatment. Most patients who are prescribed blockbuster therapies today don’t respond to the treatment, costing the health care industry billions in wasted drugs while patients continue to suffer. Scipher's platform identifies which drug will work based on the patient's fundamental disease biology, and not based on symptoms, disease classification, or medical bias. A simple test predicts which drug he/she will respond to, ensuring that most optimal treatment is prescribed from day one. The molecular data generated by our tests is then used to fuel novel target discovery to address a clear unmet medical need in patients who do not respond to any existing therapy.

SOPHiA GENETICS is a healthcare company that specializes in genomics analysis using artificial intelligence and data analysis.

Subtle, Inc., is a medical imaging software company. Our goal is to improve the quality, value, and accessibility of medical imaging by significantly reducing cost, imaging time, and radiation dose. We use the state-of-art proprietary deep learning AI algorithms to renovate the radiology workflow to deliver faster, safer and smarter solutions for imaging exams.

Treeline Biosciences is a biotech company building transformative precision medicines for patients with cancer and other serious conditions.

TRexBio is a discovery stage biotechnology company leveraging cutting edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us to identify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis. TRexBio is headquartered in South San Francisco, California.

Universal Diagnostics S.A. (UDX) is a Spanish in-vitro diagnostics company developing minimally-invasive, blood-based solutions for detecting cancer early when treatment options are more plentiful and survival rates are still high. UDX believes that the best way to fight against cancer is by detecting it early. The UDX diagnostic platform is designed to detect various cancer types, e.g. colorectal, prostate, liver, pancreatic lung, breast cancer (>50% of all new cancer cases p.a.) via one simple blood test. The assays rely on a curated set of proprietary methylation marker panels; a simple blood sample collected as part of a routine check-up, can be processed at a reference laboratory or hospital using standard equipment and then uploaded to the UDX Cloud for final algorithmic analysis. UDX's first marker panel is a colorectal cancer screening test. The test identifies individuals who need to be referred for colonoscopy. Colorectal cancer is the 3rd most frequent cancer and 2nd deadliest cancer worldwide. The challenge is that colorectal cancer is mostly detected in late stages, with significantly decreased survival rates (11% survival rate in stage IV vs. 85% survival rate in stage I). To develop the test and execute its R&D and operations, UDX partners with international research institutions, hospitals, universities, and biobanks around the globe.

Viomeanalyzes your microbiome and uses artificial intelligence to process the results and provide dietary advice.

Visterra is a clinical stage biotechnology company committed to developing innovative antibody-based therapies for the treatment of patients with kidney diseases and other hard-to-treat diseases. Our proprietary technology platform enables the design and engineering of precision antibody-based product candidates that specifically bind to, and modulate, key disease targets. Applying this technology to disease targets that are not adequately addressed by traditional therapeutic approaches, we are developing a robust pipeline of novel therapies for patients with unmet needs. Our most advanced program is in Phase 2 clinical development. In addition, Visterra has established a number of partnerships to progress novel antibodies engineered to treat significant diseases with limited treatment options.